Oppenheimer analyst Mark Breidenbach assumes Cue Biopharma (NASDAQ:CUE) with a Outperform rating and announces Price Target of $10.
Oppenheimer Assumes Cue Biopharma at Outperform, Announces Price Target of $10
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.